How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% [Yahoo! Finance]
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Actuate Therapeutics (NASDAQ:ACTU) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation [Yahoo! Finance]
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.